Bictegravir-Based Antiretroviral Therapy-Associated Accelerated Hyperglycemia and Diabetes Mellitus-Reference-Cited by-同舟云学术

Bictegravir-Based Antiretroviral Therapy-Associated Accelerated Hyperglycemia and Diabetes Mellitus

Published:2021-04-16 Issue:5 Volume:8 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Nolan Nathanial S¹^ORCID,Adamson Samantha²,Reeds Dominic³,O’Halloran Jane A¹

Affiliation:

1. Department of Medicine, Division of Infectious Diseases, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA

2. Department of Medicine, Division of Endocrinology, Metabolism and Lipid Research, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA

3. Department of Medicine, Center for Human Nutrition, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA

Abstract

Abstract Integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) is first line for treatment of people with human immunodeficiency virus (PWH). Emerging data suggest the possibility of adverse metabolic effects of these medications. We describe 3 cases in which PWH developed hyperglycemia and ketoacidosis within months of being switched to bictegravir-based ART.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Link

http://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofab077/37096106/ofab077.pdf

Reference14 articles.

1. 340. Prevalence of type II diabetes mellitus among patients living with HIV in the United States;Birabaharan;Open Forum Infect Dis,2019

2. Risk of incident diabetes mellitus, weight gain, and their relationships with integrase inhibitor–based initial antiretroviral therapy among persons with human immunodeficiency virus in the United States and Canada;Rebeiro;Clin Infect Dis,2020

3. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada;Bourgi;J Int AIDS Soc,2020

4. Dolutegravir-associated hyperglycaemia in patients with HIV;Lamorde;Lancet HIV,2020

5. Integrase strand transfer inhibitor-associated diabetes mellitus: a case report;Fong;Int J STD AIDS,2017

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic Complications Associated with Use of Integrase Strand Transfer Inhibitors (InSTI) for the Treatment of HIV-1 Infection: Focus on Weight Changes, Lipids, Glucose and Bone Metabolism;Current HIV/AIDS Reports;2024-08-29

2. Increased incidence of diabetes in people living with HIV treated with first‐line integrase strand transfer inhibitors: A French multicentre retrospective study;HIV Medicine;2024-08-28

3. Blood glucose outcomes of anti-retroviral therapy naïve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks;BMC Infectious Diseases;2024-07-29

4. Risk factors for progression from prediabetes to diabetes among older people with HIV;AIDS;2024-06-25

5. Clinical considerations when switching antiretroviral therapy;Expert Review of Clinical Pharmacology;2024-06-17